Stryker Corporation (SYK)

From the record

Stryker Corporation's filings since 2017 show 1 warning event: a material cybersecurity incident (8-K item 1.05, the latest 2026-04-09) (its current reports).

From the record

Stryker Corporation's 10 filed years say what it did: revenue went from $11 billion in fiscal 2016 to $25 billion in fiscal 2025, up 9.3% a year; it rose in 8 of 9 years; the deepest fall was 4% from fiscal 2019 to fiscal 2020; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Stryker Corporation's diluted share count grew about 0.4% a year, and dividends and buybacks returned about 28% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 63 sales (6 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-09 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Stryker Corporation earned about 14 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 34 cents per dollar of everything the company owns. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).

From the record

Stryker Corporation's standing among 109 graded names in its industry family: revenue of $25 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 12.9% ranks in the top 14%; revenue growth of 10.8% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

From the record

Stryker Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Lobo, Kevin (Chair and CEO, as filed), filing under that title since 2013-03-25, 13.6 years (top 9% of its family); the 21 officers and directors filing in the last fifteen months have been on the record a median of 6.5 years (top 30%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 21 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Stryker Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $4.0 billion against debt of $15 billion leaves -22.7% of its assets as net cash, bottom 15% of its family; cash from operations less capital spending is 17.1% of revenue (top 12%); a gross margin of 64% (top 42%); research spending of 6.5% of revenue (bottom 31%) (its annual report).

From the record

Stryker Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 10.8% a year over the last three filed years against 9.3% over all 10, speeding up (top 29% of its family); the newest year grew 11.2% (bottom 43%); research spending grew 3.7% a year (bottom 44%); capital spending grew 9% a year (top 38%) (its annual reports). Stryker Corporation reported 2 lines of business in fiscal 2025: Med Surg and Neurotechnology at $16 billion (62%), Orthopaedics and Spine at $9.5 billion (38%); 2 of 2 grew against the year before (its annual report).

From the record

Stryker Corporation's newest year against its own record: revenue of $25 billion in fiscal 2025 came in 0.4% above the $25 billion its prior three years' pace pointed to (top 37% of its family); net income of $3.2 billion against a prior three-year average of $2.8 billion (top 50%); a net margin of 12.9% against 13.8% before (bottom 26%) (its annual reports).